Foghorn Therapeutics' positive earnings report, beating EPS estimates by 25% and showing revenue growth, typically indicates a positive short-term impact on the stock price. However, it's important to note that despite beating last quarter's EPS estimate, the share price dropped by 3.0% the following day, suggesting that market reactions can be unpredictable and influenced by factors beyond just earnings performance.